Remgro and Investment Holding Limited (IHL) have signed an implementation agreement to restructure their shared interests in Mediclinic Holdings. The move would split the combined group along geographic lines. Remgro would become the sole owner of Mediclinic Southern Africa (MCSA). IHL would take 100% of Hirslanden, Mediclinic’s Swiss business.
Remgro, chaired by Johann Rupert, and IHL currently each hold 50% of Mediclinic Holdings through wholly owned subsidiaries. The latest agreement follows a cautionary process flagged earlier this year. It signals that the parties now intend to proceed with the transaction, subject to approvals.
Mediclinic Restructuring: How the Two-Part Transaction Works
The transaction has two linked components. First, Mediclinic Holdings will sell all shares in Hirslanden to IHL. Second, Remgro will acquire all shares in MCSA from Mediclinic Holdings. Each component will be executed for the same consideration: $950m.
Mediclinic Holdings sits above the “Combined Mediclinic Group”. That includes the Hirslanden Group (Switzerland), the MCSA Group (Southern Africa), the EHH Group (Middle East), and a minority interest in UK-listed Spire Healthcare.
For healthcare operators and suppliers, the MCSA perimeter matters. Remgro’s stake would include MCSA’s interests in subsidiaries and associates, including Intercare and ER24 EMS.
What Stays Shared in the Middle East and the UK
While ownership will be separated in Switzerland and Southern Africa, Remgro and IHL plan to maintain joint exposure to the group’s Middle East operations. The EHH Group manages those operations. The partners will also retain the shared interest linked to Spire Healthcare in the UK.
This structure keeps both investors positioned in markets outside their “home” territories. At the same time, it removes the operational complexity of co-owning the two largest regional platforms. Remgro has framed the plan as a way to sharpen leadership focus and local decision-making.
Mediclinic Restructuring: Why Full Ownership is the Strategic Goal
Remgro argues that healthcare delivery is being reshaped by fast-moving regulatory change, shifting patient expectations, and rapid advances in clinical practice and technology. It also points to rising pressure from chronic disease, ageing populations, and pricing and compliance demands.
Against that backdrop, the company believes full ownership in each party’s home market will improve strategic alignment and speed up responses to local conditions. In practical terms, that could mean quicker capital decisions, clearer accountability, and a more direct relationship with regulators, clinicians, and funders.
The proposed transaction remains conditional on approvals from relevant Swiss and South African authorities.
Read the Original Article (May require a subscription)